Notice2024-13621
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 21, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 120 (Friday, June 21, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52097]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-13621]
[[Page 52097]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness
Consortium
Notice is hereby given that, on April 12, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical Manufacturing
Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing changes in its membership. The
notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances.
Specifically, A-line, Inc., Signal Hill, CA; API Innovation Center,
St. Louis, MO; AVS Bio, Norwich, CT; Advanced Concept Innovations,
Lakeland, FL; Afton Scientific, Charlottesville, VA; Alchem
Laboratories Corp., Alachua, FL; AmerStem, Inc., Camarillo, CA;
American Medicines Company, PBC, Davisville, WV; American Type Culture
Collection, Manassas, VA; Amyris, Inc., Emeryville, CA; AntoXa Corp.,
Toronto, CANADA; Apertus Pharmaceuticals LLC, Ballwin, MO; Argonaut
Manufacturing Services, Inc., Carlsbad, CA; Asha Therapeutics LLC,
Tampa, FL; Attogene Corp., Austin, TX; BASF Corp., Florham Park, NJ;
BCG Federal Corp., Washington, DC; BDO Public Sector LLC, McLean, VA;
Batavia Biosciences, Inc., Woburn, MA; Benuvia Operations LLC, Round
Rock, TX; Bionova Scientific LLC, Fremont, CA; Biosortia
Pharmaceuticals, Inc., Dublin, OH; Black Mesa Technology, Inc.,
Bedford, MA; Blu Zone Bioscience & Supply Chain Solutions, LLC,
Frederick, MD; Bracane Company, Inc., Plano, TX; CGCN, Washington, DC;
CMC Pharmaceuticals, Inc., Solon, OH; Capra Biosciences, Inc.,
Manassas, VA; ChromaTan, Inc., Lower Gwynedd, PA; Concept to Market
LLC, Monrovia, MD; Cornerstone Chemical Company, Metairie, LA; Corning,
Inc., Corning, NY; CuriRx, Inc., Wilmington, MA; DEKA Research &
Development Corp., Manchester, NH; DMC Biotechnologies, Inc., Boulder,
CO; Dyadic International, Inc., Jupiter, FL; EriVan Bio, Alachua, FL;
EverGlade Consulting LLC, Houston, TX; Evimero, Tuscaloosa, AL;
FUJIFILM Diosynth Biotechnologies USA, Inc., Morrisville, NC; Fisher
BioServices, Inc., Rockville, MD; Foamtec International LLC, Waco, TX;
Fraunhofer USA, Plymouth, MI; HDT Bio Corp., Seattle, WA; HERMES, LLC,
Wilmington, NC; Health Blockchain Convergence, Inc., Tysons Corner, VA;
INTACT SOLUTIONS LLC, New Milford, CT; InflaRx GmbH, Jena, GERMANY;
Interbiome Partners LLC, Rockville, MD; Jubilant HollisterStier CMO,
Spokane, WA; Kemp Proteins, Frederick, MD; LaCire LLC, Alexandria, VA;
Latham BioPharm Group, Elkridge, MD; MalarVx, Inc., Seattle, WA;
Mallinckrodt Specialty Generics dba SpecGx LLC, Webster Groves, MO;
Manus Bio, Inc., Waltham, MA; Medical Countermeasures Coalition,
Washington, DC; Meissner Filtration Products, Inc., Camarillo, CA;
Michael Best Strategies, Washington, DC; MilliporeSigma, Burlington,
MA; Nature's Toolbox, Inc., Rio Rancho, NM; New Horizon Biotech, Inc.,
Nazareth, PA; NewAge Industries, Inc., Southampton, PA; Nipro
PharmaPackaging Americas Corp., Millville, NJ; On Demand
Pharmaceuticals, Inc., Rockville, MD; PPD Development, L.P.,
Wilmington, NC; Par Sterile Product LLC, Rochester, MI; PharmaJet,
Golden, CO; Phlow Corp., Richmond, VA; Prestige Ameritech, Ltd., North
Richland Hills, TX; ProQuality Network LLC, Dorado, PUERTO RICO;
Proteios Technology, Inc., Issaquah, WA; Quantum Four Labs LLC,
Arcadia, CA; SANARIA, Inc., Rockville, MD; SCHOTT Pharma USA, Inc.,
Lebanon, PA; SK Pharmteco, Rancho Cordova, CA; STERIS Corp., Mentor,
OH; Scorpius Biomanufacturing, Inc., San Antonio, TX; Sentio
BioSciences LLC, Maryland Heights, MO; Sepragen Corp., Union City, CA;
Shabas Solutions LLC, Fairfax, VA; Societal CDMO Inc., Gainesville, GA;
Sotera Health Company, Broadview Heights, OH; Southwest Research
Institute, San Antonio, TX; Strategic Marketing Innovations,
Washington, DC; TEGA Therapeutics, Inc., San Diego, CA; TFF
Pharmaceuticals, Inc., Fort Worth, TX; Tenagrity Solutions LLC,
Fairfax, VA; Texas A&M Engineering Experiment Station, Bryan, TX; Texas
Biomedical Research Institute, San Antonio, TX; Thaddeus Medical
Systems, Inc., Rochester, MN; The United States Pharmacopeial
Convention, Inc., Rockville, MD; Third Pole, Inc., Waltham, MA; Tonix
Pharmaceuticals Holding Corp., Chatham, NJ; TriLink BioTechnologies
LLC, San Diego, CA; US Specialty Formulations, Allentown, PA;
University of Delaware, Newark, DE; Vaxess Technologies, Inc.,
Cambridge, MA; Wheeler Bio, Inc., Oklahoma City, OK; and Zalgen Labs
LLC, Frederick, MD, have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and the BIOMAP-CONSORTIUM intends to
file additional written notifications disclosing all changes in
membership.
On January 5, 2024, the BIOMAP-CONSORTIUM filed its original
notification pursuant to section 6(a) of the Act. The Department of
Justice published a notice in the Federal Register pursuant to section
6(b) of the Act on April 16, 2024 (89 FR 26923).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-13621 Filed 6-20-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on June 21, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.